Title
Paradigm shifts in lung cancer as defined in the new IASLC/ATS/ERS lung adenocarcinoma classification Paradigm shifts in lung cancer as defined in the new IASLC/ATS/ERS lung adenocarcinoma classification
Author
Faculty/Department
Faculty of Medicine and Health Sciences
Publication type
article
Publication
Copenhagen ,
Subject
Human medicine
Source (journal)
The European respiratory journal. - Copenhagen
Volume/pages
38(2011) :2 , p. 239-243
ISSN
0903-1936
ISI
000293280400002
Carrier
E
Target language
English (eng)
Full text (Publishers DOI)
Affiliation
University of Antwerp
Abstract
The new international multidisciplinary lung adenocarcinoma classification is sponsored by the European Respiratory Society (ERS), as well as the International Association for the Study of Lung Cancer (IASLC) and the American Thoracic Society (ATS) [ 1]. This classification is now published in the Journal of Thoracic Oncology, the official journal of the IASLC. Under the scientific oversight of the ATS and ERS, the classification project involved a systematic review to provide an evidence-based foundation with specific recommendations. For decades, the field of lung cancer has been relatively static with few major advances. However, in the past 56 yrs this has changed to a rapidly evolving field. At the heart of this change is the impact of the molecular discovery that the activating mutations in the epidermal growth factor receptor ( EGFR) are a marker for response and improved progression-free survival with tyrosine kinase inhibitor (TKI) therapy compared to conventional chemotherapy in advanced lung adenocarcinoma patients [ 2 5]. In this editorial, we summarise a series of major paradigm shifts that are outlined in this classification that will result in major changes in the approach to diagnosis of lung cancer compared to those outlined in previous World Health Organization (WHO) classifications. While this classification is primarily focused on lung adenocarcinoma, many of the recommendations will impact on how all histologic types of lung cancer are diagnosed in the future. This classification is divided into two major components: classification based on resection specimens ( table 1 ) and on small biopsies and cytology ( table 2 ).
E-info
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000293280400002&DestLinkType=RelatedRecords&DestApp=ALL_WOS&UsrCustomerID=ef845e08c439e550330acc77c7d2d848
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000293280400002&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=ef845e08c439e550330acc77c7d2d848
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000293280400002&DestLinkType=CitingArticles&DestApp=ALL_WOS&UsrCustomerID=ef845e08c439e550330acc77c7d2d848
Handle